Bladder cancer is the fifth most common malignancy in the USA and the most expensive to treat on a per-patient basis.
Despite its prevalence, morbidity, mortality and associated cost of management, bladder cancer remains grossly under-recognized as a public health concern and underfunded scientifically. Although 5-year survival rates for patients with prostate or kidney cancer have improved tremendously in the past 30 years, progress in bladder cancer has stalled. A renewed interest from the clinical and research communities, as well as a young and eager advocacy network, are raising the profile of bladder cancer. As awareness and funding of bladder cancer increase, improved diagnostics, therapeutics and health services for patients with the disease will develop accordingly.
Written by:
Kaplan AL, Litwin MS, Chamie K. Are you the author?
Department of Urology, Health Services Research Group, David Geffen School of Medicine at UCLA, 924 Westwood Boulevard, Suite 1000, Los Angeles, CA 90024, USA.
Reference: Nat Rev Urol. 2013 Aug 27. Epub ahead of print.
doi: 10.1038/nrurol.2013.180
PubMed Abstract
PMID: 23979659
UroToday.com Bladder Cancer Section
